Getinge announces today that it will purchase High Purity New England, a Smithfield, Rhode Island–based provider of custom single-use products for bioprocessing applications. The Sweden-based life sciences giant will pay SEK 1.3 billion ($120 million)for all of privately-held High Purity New England’s outstanding shares at closing. In addition, there could be a maximum earn out…

The pharmaceutical and biotech industries have experienced a surge of high-profile acquisitions and mergers in the first few months of the year, marking a notable trend in pharma M&A 2023. From Merck’s $11 billion acquisition of Prometheus Biosciences to Pfizer’s $43 billion purchase of Seagen, these deals highlight a focus on strengthening core assets and…